Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688064 · ClinicalTrials.gov registry record · Phase 3
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 459
- Enrollment target
NCT00688064 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 459 participants.
The verdict
NCT00688064, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 459 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% / Benzoyl Peroxide (quoted as BPO) 2.5% Gel associated with Doxycycline Hyclate 100 mg Tablets compared to Adapalene 0.1% /Benzoyl Peroxide 2.5% Vehicle Gel associated with Doxycycline Hyclate 100 mg Tablets, in the treatment of severe acne vulgaris. The safety of the two treatment regimens will also be evaluated.
Interventions
- DRUG Adapalene BPO Gel associated with Doxycyline Hyclate
- DRUG Vehicle Gel associated with Doxycycline Hyclate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688064
The ClinicalTrials.gov registry entry for NCT00688064 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adapalene BPO Gel associated with Doxycyline Hyclate is the first listed.
NCT00688064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688064 about?
NCT00688064 is a clinical study titled "Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris". The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% / Benzoyl Peroxide (quoted as BPO) 2.5% Gel associated with Doxycycline Hyclate 100 mg Tablets compared to Adapalene 0.1% /Benzoyl Peroxide 2.5% Vehicle Gel associated with Doxycycline Hyclate 100 mg Tablets, in the treatment...
What is the current status of trial NCT00688064?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2008-08. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00688064?
The interventions under investigation include: Adapalene BPO Gel associated with Doxycyline Hyclate (DRUG), Vehicle Gel associated with Doxycycline Hyclate (DRUG).
Who is sponsoring clinical trial NCT00688064?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.